Literature DB >> 22324512

Functional efficacy of adenosine A₂A receptor agonists is positively correlated to their receptor residence time.

Dong Guo1, Thea Mulder-Krieger, Adriaan P IJzerman, Laura H Heitman.   

Abstract

BACKGROUND AND PURPOSE The adenosine A(2A) receptor belongs to the superfamily of GPCRs and is a promising therapeutic target. Traditionally, the discovery of novel agents for the A(2A) receptor has been guided by their affinity for the receptor. This parameter is determined under equilibrium conditions, largely ignoring the kinetic aspects of the ligand-receptor interaction. The aim of this study was to assess the binding kinetics of A(2A) receptor agonists and explore a possible relationship with their functional efficacy. EXPERIMENTAL APPROACH We set up, validated and optimized a kinetic radioligand binding assay (a so-called competition association assay) at the A(2A) receptor from which the binding kinetics of unlabelled ligands were determined. Subsequently, functional efficacies of A(2A) receptor agonists were determined in two different assays: a novel label-free impedance-based assay and a more traditional cAMP determination. KEY RESULTS A simplified competition association assay yielded an accurate determination of the association and dissociation rates of unlabelled A(2A) receptor ligands at their receptor. A correlation was observed between the receptor residence time of A(2A) receptor agonists and their intrinsic efficacies in both functional assays. The affinity of A(2A) receptor agonists was not correlated to their functional efficacy. CONCLUSIONS AND IMPLICATIONS This study indicates that the molecular basis of different agonist efficacies at the A(2A) receptor lies within their different residence times at this receptor.
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22324512      PMCID: PMC3402809          DOI: 10.1111/j.1476-5381.2012.01897.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  46 in total

Review 1.  Biochemical mechanisms of drug action: what does it take for success?

Authors:  David C Swinney
Journal:  Nat Rev Drug Discov       Date:  2004-09       Impact factor: 84.694

2.  Inhaled adenosine A(2A) receptor agonists for the treatment of chronic obstructive pulmonary disease.

Authors:  Simon J Mantell; Peter T Stephenson; Sandra M Monaghan; Graham N Maw; Michael A Trevethick; Michael Yeadon; Ruth F Keir; Don K Walker; Rhys M Jones; Matthew D Selby; David V Batchelor; Stuart Rozze; Helene Chavaroche; Tim J Hobson; Peter G Dodd; Arnaud Lemaitre; Karen N Wright; Emilio F Stuart
Journal:  Bioorg Med Chem Lett       Date:  2008-01-12       Impact factor: 2.823

Review 3.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

4.  Real-time cellular impedance measurements detect Ca(2+) channel-dependent oscillations of morphology in human H295R adrenoma cells.

Authors:  Athanasios Denelavas; Franziska Weibel; Michael Prummer; Alexander Imbach; Roger G Clerc; Christian M Apfel; Cornelia Hertel
Journal:  Biochim Biophys Acta       Date:  2011-01-22

5.  Evaluation of cannabinoid receptor 2 and metabotropic glutamate receptor 1 functional responses using a cell impedance-based technology.

Authors:  Paola Scandroglio; Rossella Brusa; Gianluca Lozza; Isabella Mancini; Roberta Petrò; Angelo Reggiani; Massimiliano Beltramo
Journal:  J Biomol Screen       Date:  2010-09-01

6.  Binding of [3H]KF17837S, a selective adenosine A2 receptor antagonist, to rat brain membranes.

Authors:  H Nonaka; A Mori; M Ichimura; T Shindou; K Yanagawa; J Shimada; H Kase
Journal:  Mol Pharmacol       Date:  1994-11       Impact factor: 4.436

7.  The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist.

Authors:  Veli-Pekka Jaakola; Mark T Griffith; Michael A Hanson; Vadim Cherezov; Ellen Y T Chien; J Robert Lane; Adriaan P Ijzerman; Raymond C Stevens
Journal:  Science       Date:  2008-10-02       Impact factor: 47.728

8.  Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes.

Authors:  C Zocchi; E Ongini; S Ferrara; P G Baraldi; S Dionisotti
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

9.  Kinetic analysis of the interactions of agonists and antagonists with beta adrenergic receptors.

Authors:  M L Contreras; B B Wolfe; P B Molinoff
Journal:  J Pharmacol Exp Ther       Date:  1986-10       Impact factor: 4.030

10.  Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation.

Authors:  Guillaume Lebon; Tony Warne; Patricia C Edwards; Kirstie Bennett; Christopher J Langmead; Andrew G W Leslie; Christopher G Tate
Journal:  Nature       Date:  2011-05-18       Impact factor: 49.962

View more
  50 in total

Review 1.  The drug-target residence time model: a 10-year retrospective.

Authors:  Robert A Copeland
Journal:  Nat Rev Drug Discov       Date:  2015-12-18       Impact factor: 84.694

2.  Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time.

Authors:  Georges Vauquelin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-28       Impact factor: 3.000

Review 3.  New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2.

Authors:  Terry Kenakin
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

4.  Molecular mechanism of allosteric modulation at GPCRs: insight from a binding kinetics study at the human A1 adenosine receptor.

Authors:  Dong Guo; Suzanne N Venhorst; Arnault Massink; Jacobus P D van Veldhoven; Georges Vauquelin; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

5.  Kv 11.1 (hERG)-induced cardiotoxicity: a molecular insight from a binding kinetics study of prototypical Kv 11.1 (hERG) inhibitors.

Authors:  Z Yu; A P IJzerman; L H Heitman
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

6.  Binding Thermodynamics and Kinetics Calculations Using Chemical Host and Guest: A Comprehensive Picture of Molecular Recognition.

Authors:  Zhiye Tang; Chia-En A Chang
Journal:  J Chem Theory Comput       Date:  2017-12-14       Impact factor: 6.006

7.  Molecular docking screening using agonist-bound GPCR structures: probing the A2A adenosine receptor.

Authors:  David Rodríguez; Zhang-Guo Gao; Steven M Moss; Kenneth A Jacobson; Jens Carlsson
Journal:  J Chem Inf Model       Date:  2015-02-13       Impact factor: 4.956

8.  Characterization of 12 GnRH peptide agonists - a kinetic perspective.

Authors:  Indira Nederpelt; Victoria Georgi; Felix Schiele; Katrin Nowak-Reppel; Amaury E Fernández-Montalván; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2015-11-04       Impact factor: 8.739

9.  Structure-Activity Analysis of Biased Agonism at the Human Adenosine A3 Receptor.

Authors:  Jo-Anne Baltos; Silvia Paoletta; Anh T N Nguyen; Karen J Gregory; Dilip K Tosh; Arthur Christopoulos; Kenneth A Jacobson; Lauren T May
Journal:  Mol Pharmacol       Date:  2016-05-02       Impact factor: 4.436

10.  Ligand-dependent activation and deactivation of the human adenosine A(2A) receptor.

Authors:  Jianing Li; Amanda L Jonsson; Thijs Beuming; John C Shelley; Gregory A Voth
Journal:  J Am Chem Soc       Date:  2013-05-29       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.